Skip to content
naulon
Not checkedNot checked for notices yet.

Synergistic Effect of Potassium Clavulanate in Combination withCefamandol and Ceftazidime on B- Lactamase, Extracted From Resistant E.coli

Siham S. Shaokat, Hamoudi A. Hameed

Iraqi Journal of Pharmaceutical Sciences · 2017

doi:10.31351/vol15iss2pp8-16 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

The aim of this study was to evaluate in-vitro activity of Cefamandol and Ceftazidime, in combination with potassium clavulanate against 10 uropathogenic E.coli isolated from patients with chronic complicated urinary tract infections (UTIs), these isolates were identified by the Api identification systems.The antimicrobial susceptibility tests were determined by Kirby-Bauer method and the minimum inhibitory concentrations of Cefamandol and Ceftazidime, were determined, by tube method. These isolates were resistant to Ampicillin (Amp), Amoxicillin (Amo), Carbenicillin (Cb), Ticarcillin (Tic), Amoxicillin\ Potassium Clavulanate {Augmentin}, (Amo\CA), Ticarcillin\ Potassium Clavulanate {Timentin} (Tic\CA), Cefamandol (Cfm) and Ceftazidime (Cfz), also resistant to other antibiotics, such as Tetracycline, Chloramphenicol, Trimethoprim and (50% of the isolates were resistant to Nalidixic acid and Rifampicin). Transfer of plasmids by direct conjugation experiments were performed by mating 10 strains with recipient strain E.coliK12C 600 Rif or Nal resistant, and cell free b- lactamases were prepared and detected by macro-iodometric method. The activities of each cell free b– lactamases extract against Cfm and Cfz were determined by disks diffusion method (microbiological Masuda method) and by macro-iodometric method. The activity of b- lactamases was inhibited by the addition of Potassium Clavulanate. Conclusion: Good effectiveness of Cfm\ CA and Cfz\ CA was obtained against resistant strains of E.coli due to complicated urinary tract infection (UTIs). Key words: b- lactamases, Cefamandol, Ceftazidime, Timentin and Augmentin.

Abstract licence: CC BY

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.